Wells Fargo & Company Roivant Sciences Ltd. Transaction History

Wells Fargo & Company

$434 Billion
Q3 2024

A detailed history of Wells Fargo & Company transactions in Roivant Sciences Ltd. stock. As of the latest transaction made, Wells Fargo & Company holds 4,075 shares of ROIV stock, worth $48,900. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,075

Previous 3,027 34.62%

Holding current value

$48,900

Previous $31,000 51.61%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$10.17 - $12.5 $10,658 - $13,100	1,048 Added 34.62%	4,075 $47,000
Q2 2024 Aug 13, 2024	SELL	$10.36 - $11.74 $141,155 - $159,957	-13,625 Reduced 81.82%	3,027 $31,000
Q1 2024 May 10, 2024	SELL	$9.87 - $11.8 $92,945 - $111,120	-9,417 Reduced 36.12%	16,652 $175,000
Q4 2023 Feb 09, 2024	SELL	$8.38 - $11.58 $1.05 Million - $1.45 Million	-125,465 Reduced 82.8%	26,069 $292,000
Q3 2023 Nov 13, 2023	BUY	$9.76 - $13.19 $121,043 - $163,582	12,402 Added 8.91%	151,534 $1.77 Million
Q2 2023 Aug 15, 2023	BUY	$7.09 - $10.08 $90,801 - $129,094	12,807 Added 10.14%	139,132 $1.4 Million
Q1 2023 May 12, 2023	BUY	$6.92 - $9.98 $869,068 - $1.25 Million	125,588 Added 17040.43%	126,325 $932,000
Q4 2022 Feb 13, 2023	BUY	$3.36 - $7.99 $124 - $295	37 Added 5.29%	737 $5,000
Q3 2022 Nov 14, 2022	BUY	$0.51 - $4.84 $26 - $251	52 Added 8.02%	700 $2,000
Q2 2022 Aug 12, 2022	BUY	$2.81 - $4.84 $146 - $251	52 Added 8.72%	648 $3,000
Q1 2022 May 16, 2022	BUY	$4.74 - $9.91 $37 - $79	8 Added 1.36%	596 $3,000
Q4 2021 Feb 14, 2022	BUY	$5.86 - $13.52 $3,445 - $7,949	588 New	588 $6,000

Others Institutions Holding ROIV

# of Institutions

310

Shares Held

507M

Call Options Held

1.26M

Put Options Held

2.52M

View Full List

About Roivant Sciences Ltd.

Ticker ROIV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 704,382,976
Market Cap $8.45B
Description
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...

More about ROIV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Roivant Sciences Ltd. Transaction History